Patents by Inventor Jonathan Mark Sutton

Jonathan Mark Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic Compounds as RET Kinase Inhibitors
    Publication number: 20210047334
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 18, 2021
    Applicant: Cancer Research Technology Limited
    Inventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • Heterocyclic compounds as RET kinase inhibitors
    Patent number: 10844067
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: November 24, 2020
    Assignee: Cancer Research Technology Limited
    Inventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • Compounds Useful as RET Inhibitors
    Publication number: 20200157107
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: April 13, 2018
    Publication date: May 21, 2020
    Applicant: Cancer Research Technology Limited
    Inventors: Allan Jordan, Rebecca Newton, George Hynd, Jonathan Mark Sutton, Bohdan Waszkowycz
  • CHEMICAL COMPOUNDS AS ANTIBIOTICS
    Publication number: 20200155509
    Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.
    Type: Application
    Filed: March 21, 2018
    Publication date: May 21, 2020
    Applicant: Antabio SAS
    Inventors: Simon LEIRIS, David Thomas DAVIES, Martin EVERETT, Nicolas SPRYNSKI, Jonathan Mark SUTTON, Michael Steven BODNARCHUK, Thomas David PALLIN, Andrew Peter CRIDLAND, Toby Jonathan BLENCH, David Edward CLARK, Richard Leonard ELLIOTT, Lilha BEYRIA
  • HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190263819
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 29, 2019
    Inventors: Allan Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190106425
    Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: April 18, 2017
    Publication date: April 11, 2019
    Inventors: Allan Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • Pyrazolone compounds having human neutrophil elastase inhibitory properties
    Patent number: 10172830
    Abstract: Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 8, 2019
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Jonathan Mark Sutton, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • Compounds
    Patent number: 10023558
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: July 17, 2018
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark Sutton, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • Pyrimidinone compounds which are HNE inhibitors
    Patent number: 9868740
    Abstract: This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: January 16, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • NOVEL COMPOUNDS
    Publication number: 20180009787
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark SUTTON, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • NOVEL COMPOUNDS
    Publication number: 20170340611
    Abstract: Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark SUTTON, Robert Andrew HEALD, Andrew Stephen Robert JENNINGS, Carmelida CAPALDI, Elisabetta ARMANI
  • Pyrimidinone compounds as human neutrophil elastase inhibitors
    Patent number: 9828382
    Abstract: Pyrimidone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and condition in which HNE is implicated.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 28, 2017
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • Compounds
    Patent number: 9802919
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: October 31, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Jonathan Mark Sutton, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • NOVEL COMPOUNDS
    Publication number: 20170101413
    Abstract: This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
    Type: Application
    Filed: June 12, 2014
    Publication date: April 13, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian ALCARAZ, Robert Andrew HEALD, Jonathan Mark SUTTON, Elisabetta ARMANI, Carmelida CAPALDI
  • Compounds
    Patent number: 9573955
    Abstract: Heterocyclic compounds and salts according to formula (I), which are pyrimidinone derivatives, described herein exhibit human neutrophil elastase inhibitory properties, and useful for treating diseases or conditions in which HNE is implicated.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: February 21, 2017
    Assignee: Chiese Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • Compounds
    Patent number: 9487528
    Abstract: Compounds of formula (I), described herein, exhibit human neutrophil elastase inhibitory properties, and are useful for the treatment of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 8, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Elisabetta Armani, Carmelida Capaldi, Jonathan Mark Sutton, Robert Andrew Heald
  • NOVEL COMPOUNDS
    Publication number: 20160251362
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 1, 2016
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: LILIAN ALCARAZ, ROBERT ANDREW HEALD, JONATHAN MARK SUTTON, ELISABETTA ARMANI, CARMELIDA CAPALDI
  • Compounds
    Patent number: 9409870
    Abstract: Compounds of formula (I) described herein are imidazolone derivatives having human neutrophil elastase (HNE) inhibitory properties and are useful for the treatment of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: August 9, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta Armani, Carmelida Capaldi, Jonathan Mark Sutton, Robert Andrew Heald
  • NOVEL COMPOUNDS
    Publication number: 20160168101
    Abstract: Compounds of formula (I) described herein are imidazolone derivatives having human neutrophil elastase (HNE) inhibitory properties and are useful for the treatment of diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: November 27, 2015
    Publication date: June 16, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta ARMANI, Carmelida CAPALDI, Jonathan Mark SUTTON, Robert Andrew HEALD
  • Pyrimidinone compounds as human neutrophil elastase inhibitors
    Patent number: 9365577
    Abstract: Pyrimidinone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HINE is implicated.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 14, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi